NYSE:TARO

Taro Pharmaceutical Industries Competitors

$76.68
+0.71 (+0.93 %)
(As of 04/21/2021 01:53 PM ET)
Add
Compare
Today's Range
$76.63
Now: $76.68
$76.90
50-Day Range
$70.70
MA: $75.22
$78.80
52-Week Range
$53.95
Now: $76.68
$80.00
Volume296 shs
Average Volume30,380 shs
Market Capitalization$2.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92

Competitors

Taro Pharmaceutical Industries (NYSE:TARO) Vs. RDY, TEVA, BHC, JAZZ, UTHR, and MRVI

Should you be buying TARO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Taro Pharmaceutical Industries, including Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), and Maravai LifeSciences (MRVI).

Taro Pharmaceutical Industries (NYSE:TARO) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Taro Pharmaceutical Industries and Dr. Reddy's Laboratories' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taro Pharmaceutical Industries$644.77 million4.55$244.24 million$6.3512.08
Dr. Reddy's Laboratories$2.32 billion4.86$259 million$2.7924.24

Dr. Reddy's Laboratories has higher revenue and earnings than Taro Pharmaceutical Industries. Taro Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Institutional & Insider Ownership

11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Taro Pharmaceutical Industries and Dr. Reddy's Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taro Pharmaceutical Industries00103.00
Dr. Reddy's Laboratories00403.00

Taro Pharmaceutical Industries presently has a consensus target price of $81.00, indicating a potential upside of 5.70%. Dr. Reddy's Laboratories has a consensus target price of $70.00, indicating a potential upside of 3.50%. Given Taro Pharmaceutical Industries' higher probable upside, analysts plainly believe Taro Pharmaceutical Industries is more favorable than Dr. Reddy's Laboratories.

Profitability

This table compares Taro Pharmaceutical Industries and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taro Pharmaceutical Industries-45.94%10.36%8.38%
Dr. Reddy's Laboratories8.23%16.33%10.79%

Summary

Dr. Reddy's Laboratories beats Taro Pharmaceutical Industries on 9 of the 13 factors compared between the two stocks.

Taro Pharmaceutical Industries (NYSE:TARO) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Taro Pharmaceutical Industries and Teva Pharmaceutical Industries' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taro Pharmaceutical Industries$644.77 million4.55$244.24 million$6.3512.08
Teva Pharmaceutical Industries$16.89 billion0.66$-998,000,000.00$2.314.45

Taro Pharmaceutical Industries has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Institutional & Insider Ownership

11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Taro Pharmaceutical Industries and Teva Pharmaceutical Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taro Pharmaceutical Industries00103.00
Teva Pharmaceutical Industries18402.23

Taro Pharmaceutical Industries presently has a consensus target price of $81.00, indicating a potential upside of 5.70%. Teva Pharmaceutical Industries has a consensus target price of $12.2222, indicating a potential upside of 19.71%. Given Teva Pharmaceutical Industries' higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Taro Pharmaceutical Industries.

Profitability

This table compares Taro Pharmaceutical Industries and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taro Pharmaceutical Industries-45.94%10.36%8.38%
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Summary

Teva Pharmaceutical Industries beats Taro Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.

Taro Pharmaceutical Industries (NYSE:TARO) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Taro Pharmaceutical Industries and Bausch Health Companies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taro Pharmaceutical Industries$644.77 million4.55$244.24 million$6.3512.08
Bausch Health Companies$8.60 billion1.22$-1,788,000,000.00$4.436.64

Taro Pharmaceutical Industries has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Institutional & Insider Ownership

11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Comparatively, 12.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Taro Pharmaceutical Industries and Bausch Health Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taro Pharmaceutical Industries00103.00
Bausch Health Companies14702.50

Taro Pharmaceutical Industries presently has a consensus target price of $81.00, indicating a potential upside of 5.70%. Bausch Health Companies has a consensus target price of $32.5833, indicating a potential upside of 11.51%. Given Bausch Health Companies' higher probable upside, analysts plainly believe Bausch Health Companies is more favorable than Taro Pharmaceutical Industries.

Profitability

This table compares Taro Pharmaceutical Industries and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taro Pharmaceutical Industries-45.94%10.36%8.38%
Bausch Health Companies-23.92%173.20%4.21%

Summary

Bausch Health Companies beats Taro Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.

Taro Pharmaceutical Industries (NYSE:TARO) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Taro Pharmaceutical Industries and Jazz Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taro Pharmaceutical Industries$644.77 million4.55$244.24 million$6.3512.08
Jazz Pharmaceuticals$2.16 billion4.41$523.37 million$14.6011.60

Jazz Pharmaceuticals has higher revenue and earnings than Taro Pharmaceutical Industries. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Institutional & Insider Ownership

11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. Comparatively, 95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Taro Pharmaceutical Industries and Jazz Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taro Pharmaceutical Industries00103.00
Jazz Pharmaceuticals111702.84

Taro Pharmaceutical Industries presently has a consensus target price of $81.00, indicating a potential upside of 5.70%. Jazz Pharmaceuticals has a consensus target price of $187.3684, indicating a potential upside of 11.16%. Given Jazz Pharmaceuticals' higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Taro Pharmaceutical Industries.

Profitability

This table compares Taro Pharmaceutical Industries and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taro Pharmaceutical Industries-45.94%10.36%8.38%
Jazz Pharmaceuticals7.86%20.16%10.85%

Summary

Jazz Pharmaceuticals beats Taro Pharmaceutical Industries on 11 of the 14 factors compared between the two stocks.

Taro Pharmaceutical Industries (NYSE:TARO) and United Therapeutics (NASDAQ:UTHR) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Taro Pharmaceutical Industries and United Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taro Pharmaceutical Industries$644.77 million4.55$244.24 million$6.3512.08
United Therapeutics$1.45 billion6.48$-104,500,000.00($2.39)-88.24

Taro Pharmaceutical Industries has higher earnings, but lower revenue than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Institutional & Insider Ownership

11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. Comparatively, 90.1% of United Therapeutics shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Comparatively, 10.9% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Taro Pharmaceutical Industries and United Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taro Pharmaceutical Industries00103.00
United Therapeutics00703.00

Taro Pharmaceutical Industries presently has a consensus target price of $81.00, indicating a potential upside of 5.70%. United Therapeutics has a consensus target price of $219.5714, indicating a potential upside of 4.25%. Given Taro Pharmaceutical Industries' higher probable upside, analysts plainly believe Taro Pharmaceutical Industries is more favorable than United Therapeutics.

Profitability

This table compares Taro Pharmaceutical Industries and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taro Pharmaceutical Industries-45.94%10.36%8.38%
United Therapeutics33.25%15.48%11.31%

Summary

United Therapeutics beats Taro Pharmaceutical Industries on 8 of the 13 factors compared between the two stocks.

Taro Pharmaceutical Industries (NYSE:TARO) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Taro Pharmaceutical Industries and Maravai LifeSciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taro Pharmaceutical Industries$644.77 million4.55$244.24 million$6.3512.08
Maravai LifeSciencesN/AN/AN/AN/AN/A

Taro Pharmaceutical Industries has higher revenue and earnings than Maravai LifeSciences.

Institutional & Insider Ownership

11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Taro Pharmaceutical Industries and Maravai LifeSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taro Pharmaceutical Industries00103.00
Maravai LifeSciences001003.00

Taro Pharmaceutical Industries presently has a consensus target price of $81.00, indicating a potential upside of 5.70%. Maravai LifeSciences has a consensus target price of $38.1250, indicating a potential upside of 6.79%. Given Maravai LifeSciences' higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Taro Pharmaceutical Industries.

Profitability

This table compares Taro Pharmaceutical Industries and Maravai LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taro Pharmaceutical Industries-45.94%10.36%8.38%
Maravai LifeSciencesN/AN/AN/A

Summary

Taro Pharmaceutical Industries beats Maravai LifeSciences on 5 of the 8 factors compared between the two stocks.


Taro Pharmaceutical Industries Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$67.64+0.4%$11.20 billion$2.32 billion55.90
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.27+1.6%$11.04 billion$16.89 billion-2.79Upcoming Earnings
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.40+3.3%$10.11 billion$8.60 billion-5.39
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$169.31+0.7%$9.47 billion$2.16 billion53.41Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$210.89+1.6%$9.25 billion$1.45 billion19.95
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.86+1.0%$9.14 billionN/A0.00Increase in Short Interest
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.90+1.4%$8.27 billion$40.56 million-16.10
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$159.59+2.4%$7.89 billion$3.34 million-20.73
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$68.66+0.8%$7.07 billion$87.99 million-81.74
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$108.01+2.8%$7.03 billion$103.71 million-24.60Analyst Report
Insider Selling
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.37+0.0%$6.85 billion$311.33 million-126.96News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$124.74+0.2%$6.72 billion$14.98 million-15.19Unusual Options Activity
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.56+1.0%$5.80 billion$1.12 billion86.58Analyst Report
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$72.34+1.4%$5.66 billion$380.83 million-9.25Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$40.57+1.5%$5.62 billion$150,000.00-19.14Analyst Report
Analyst Revision
News Coverage
Gap Up
Perrigo logo
PRGO
Perrigo
2.3$42.57+1.2%$5.62 billion$4.84 billion-709.38Dividend Announcement
Allakos logo
ALLK
Allakos
1.7$106.17+1.9%$5.57 billionN/A-38.75
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.84+1.3%$5.37 billion$66.51 million17.31Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$82.74+3.7%$5.22 billion$1.00 billion-12.54Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.5$72.46+3.4%$4.90 billion$85.54 million0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.50+1.1%$4.57 billionN/A-6.07Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.02+0.8%$4.29 billion$6.87 million-7.15Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.79+2.7%$4.22 billion$204.89 million-37.24
I-Mab logo
IMAB
I-Mab
1.4$55.33+2.7%$4.09 billion$4.31 million-1.91
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.83+1.6%$4.03 billion$806.43 million-9.61Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.04+1.2%$3.89 billion$117.91 million-11.16
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.95+0.1%$3.70 billionN/A-6.19
LEGN
Legend Biotech
1.2$27.21+1.8%$3.55 billion$64.39 million0.00Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$66.00+0.6%$3.52 billion$1.11 billion21.22News Coverage
Gap Up
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.32+2.4%$3.50 billionN/A-20.89
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$40.95+3.4%$3.50 billionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.72+4.6%$3.43 billion$114.62 million-7.95
Insmed logo
INSM
Insmed
1.2$33.57+3.8%$3.34 billion$136.47 million-12.91
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.42+2.9%$3.33 billion$339.08 million-12.45Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$45.73+1.3%$3.26 billion$306.98 million-6.54
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.73+1.6%$3.23 billion$26.52 million-7.99Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.53+1.8%$3.21 billion$1.17 billion-44.63Insider Selling
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.05+1.7%$3.16 billion$36.13 million-68.73
Arvinas logo
ARVN
Arvinas
1.5$65.73+5.8%$3.03 billion$42.98 million-25.68Upcoming Earnings
Analyst Report
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.75+1.1%$2.96 billion$80.43 million108.34
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$108.36+0.3%$2.92 billionN/A-53.91News Coverage
OPKO Health logo
OPK
OPKO Health
1.9$4.27+3.3%$2.77 billion$901.90 million-23.72
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$64.14+2.3%$2.75 billion$421.03 million22.58News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.43+1.0%$2.65 billion$25 million-9.09Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.02+2.1%$2.64 billion$306.49 million25.87
Organogenesis logo
ORGO
Organogenesis
1.0$21.21+3.3%$2.62 billion$260.98 million-353.50News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$42.94+1.5%$2.61 billionN/A-23.59
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.89+1.1%$2.59 billion$182.24 million-8.60Analyst Upgrade
Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$42.08+1.9%$2.57 billion$2.11 million-9.11Analyst Report
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$29.62+3.2%$2.47 billion$60,000.00-9.20Analyst Revision
News Coverage
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.